A cohort of Chinese biopharmaceutical companies, including Wuhan YZY Biopharma Co., Ltd (HKG: 2496), Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266), JW Therapeutics (HKG: 2126), and CStone Pharmaceuticals (HKG: 2616), are preparing to present updates on their pipeline products at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held from May 31 to June 4, 2024, in Chicago.
YZY Bio:
YZY Bio will unveil results from a Phase II study of M701, a recombinant anti-EpCAM and CD3 human murine chimeric bispecific antibody (BsAb) injection for malignant pleural effusion caused by advanced epithelial solid tumors. The study showed that M701 treated subjects had a significantly improved puncture/drainage-Free Survival (PuFS) of 54 days compared to 24 days in the control group, and a notably improved 6-month survival rate of 35.2% versus 15.8%. The drug demonstrated overall controllable safety.
Zelgen Bio:
Zelgen Bio will update data from a Phase I/II study of its anti-PD-1/TIGIT bispecific antibody (BsAb) ZG005 in advanced solid tumors, showing an objective response rate (ORR) of 43% and a disease control rate (DCR) of 81% in 21 evaluable cervical cancer patients. The 20mg/kg group achieved an ORR of 63%, with good safety and tolerability.
Additionally, Zelgen will present a Phase I/II study for ZGGS18, a BsAb targeting vascular endothelial growth factor (VEGF) and transforming growth factor-beta (TGF-β) in advanced solid tumors. In 19 subjects with evaluable efficacy, ORR and DCR were 5.3% and 42.1%, respectively, with good safety and tolerability.
JW Therapeutics:
JW Therapeutics will present long-term survival data from the RELIANCE study for its chimeric antigen receptor (CAR) T cell therapy Carteyva (relmacabtagene autoleucel injection) in relapsed/refractory B-cell non-Hodgkin’s lymphoma (r/r B-NHL). The LBCL cohort showed an ORR of 77.6%, with a complete remission (CR) rate of 53.5% and a median time to CR of 0.95 months. The 2-year overall survival (OS) rate was 84.9%, and the 4-year OS rate was 66.7%, with 4-year OS in CR patients reaching 82.5%. Carteyva exhibited good safety, with no grade 3-4 cytokine release syndrome (CRS) or neurotoxicity (NT) observed.
CStone Pharma:
CStone Pharma will announce the latest results of a Phase Ia/Ib study for its ROR1 antibody drug conjugate (ADC) CS5001 in advanced solid tumors and lymphoma. The first eight dose levels (7 to 125 μg/kg) of Phase Ia have been assessed for dose limiting toxicity (DLT), with no DLT observed and the maximum tolerable dose (MTD) not reached. CS5001 showed good tolerance and safety, with pharmacokinetic features meeting expectations. Nine evaluable Hodgkin’s lymphoma patients had an ORR of 55.6%, and six evaluable diffuse large B-cell lymphoma (DLBCL) patients had an ORR of 50.0%. Preliminary anti-tumor activity of CS5001 was also observed in patients with non-small cell lung cancer, pancreatic cancer, breast cancer, and other solid tumors.- Flcube.com
